Donggu Bio Pharmaceutical announced on the 27th that it has signed a strategic agreement with Immunis Bio, a leader in the advanced regenerative medicine field, to jointly conduct research and business cooperation in the fields of advanced regenerative medicine and cosmetics, aiming for innovative product development and commercialization.
Through this agreement, the companies express a strong commitment to leading innovation in cell therapy, advanced regenerative medicine, beauty, and the medical industry, as well as creating new markets.
Based on its achievements in the specialty pharmaceutical sector and advanced cosmeceutical field, Donggu Bio Pharmaceutical is advancing as a total healthcare leading company by expanding its product lineup and strengthening its CDMO business. To this end, it is accelerating overseas market entry, enhancing R&D capabilities, and expanding strategic investments.
Immunis Bio is recognized for its outstanding technology in the advanced regenerative medicine field, including NK cells, stem cells, and regulatory T cells. It is engaged in the development and commercialization of advanced regenerative immune cell therapies and sells immune cell culture media and advanced functional cosmetic ingredient HYUCELL in the cosmeceutical sector.
Through the MOU, both companies will combine their core technologies and business capabilities to maximize synergy effects, showcase innovative products and services, lead domestic and international markets, and focus their efforts on successfully entering the global market.
By integrating immune cell technology, a core of advanced regenerative medicine, they will jointly conduct research and development of cell therapies and accelerate the development of high-performance cosmeceutical products applying related technologies.
They plan to launch a joint brand ampoule including a hair growth-specific ampoule and focus on increasing market share domestically and internationally through medical device approvals and joint sales, thereby strengthening their position as a global brand. They aim to satisfy consumer values and needs based on differentiated concepts and innovative technology.
Donggu Bio Pharmaceutical CEO Jo Yong-jun stated, "Through cooperation with Immunis Bio, we expect to secure new growth engines in advanced regenerative medicine and the cosmeceutical field integrating this technology, and accelerate our entry into the global market."
Immunis Bio CEO Kang Jeong-hwa explained, "Through the MOU, by combining the strengths of both companies, we expect to create innovative synergy in advanced regenerative medicine and the cosmeceutical field and present therapies, products, and services that maximize consumer satisfaction."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
